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Abstract 
Observational studies show earlier age at menarche associated with higher risk of cardiovascular 
disease although these studies could be confounded by childhood obesity or childhood 
socioeconomic position. We hypothesized that earlier age at menarche is associated with poorer 
cardiovascular risk factors using a Mendelian randomization design. We conducted a Mendelian 
randomization study in a large Southern Chinese cohort, the Guangzhou Biobank Cohort Study 
(n=12,279), to clarify the causal role of menarche in cardiovascular disease risk factors including 
blood pressure, lipids, fasting glucose, adiposity and type 2 diabetes. A genetic allele score was 
obtained from single nucleotide polymorphisms associated with age at menarche using stepwise 
regression and with cross validation. Estimates of the association of age at menarche with 
cardiovascular disease risk factors were obtained using two stage least square regression. Height 
was included as a positive control outcome. The F-statistic for the allele score (rs17268785, 
rs1859345, rs2090409, rs4452860 and rs4946651) was 19.9. Older age at menarche was 
associated with lower glucose (-0.39 mmol/L per year older menarche, 95% confidence interval 
(CI) -0.78 to -0.001) but not clearly with any other cardiovascular risk factors. Older age at 
menarche was also associated with taller height. Age at menarche did not appear to affect 
cardiovascular disease risk factors except for glucose in an inverse manner. However, these 
results need to be confirmed in larger Mendelian randomization studies.  
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Introduction 
Earlier age at menarche is associated with a poorer cardiovascular profile in different settings 
(Chang et al., 2011; Feng et al., 2008; Gallagher et al., 2011; Heys et al., 2007; Lakshman et al., 
2009). Younger age at menarche may be associated with cardiovascular disease, and its risk 
factors, as a result of particular childhood conditions prone to a higher cardiovascular risk in later 
life, such as physical inactivity and higher body mass index (BMI) in childhood (Chavarro et al., 
2004; Morris et al., 2010) Younger age of menarche is also associated with higher adult BMI, so 
associations with cardiovascular disease might be mediated by adult BMI (Lakshman et al., 2009; 
Stockl et al., 2011). Alternatively, longer life time exposure to sex hormones might be a factor in 
cardiovascular disease, which is another consequence of earlier menarche (Howard and Rossouw, 
2013; Vigen et al., 2013; Xu et al., 2013). 
 
To reduce confounding by childhood BMI, examining the relation of age at menarche with 
cardiovascular risk in settings where childhood obesity is relatively recent, such as China, 
provides a possible way forward (Ji and Cooperative Study on Childhood Obesity: Working 
Group on Obesity in, 2008). Our previous observational study in China found young age of 
menarche associated with the metabolic syndrome in older women (Heys et al., 2007), although 
residual confounding by childhood socioeconomic position or infant infections is possible 
(McDonald et al., 2016). Mendelian randomization provides an alternative approach when 
randomized controlled trials are not available or not possible. Since genetic endowment is 
randomly allocated at conception, this is analogous to the randomization process in randomized 
controlled trials, and hence is less susceptible to confounding than observational studies (Lawlor 
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et al., 2008). To our knowledge no Mendelian randomization study has examined the role of age 
at menarche in cardiovascular risk factors in older populations. A small Mendelian 
randomization study from the US only focused on age at menarche and peri-pubertal body mass 
index (Johnson et al., 2013). A genetic study showed shared genetic determinants of pubertal 
timing and health outcomes, including cardiovascular disease and diabetes, but did not formally 
estimate the effect of age of menarche on these outcomes (Day et al., 2015). To address the long 
term effect of age at menarche on cardiovascular health in an under-studied population, we 
conducted a Mendelian randomization study using a large older Southern Chinese cohort to 
examine the relation of age at menarche with cardiovascular risk factors, including blood 
pressure, lipids, glucose and adiposity traits, using genetic instruments identified from previous 
genome wide association studies (Dvornyk and Waqar-ul-Haq, 2012). Given later age at 
menarche is consistently associated with taller height (Onland-Moret et al., 2005), we considered 
height as a positive control to rule out the possibility of underpowered analyses (Lipsitch et al., 
2010). 
 
Methods 
The Guangzhou Biobank Cohort Study (GBCS) is an ongoing collaboration of Guangzhou 
Number 12 Hospital, the Universities of Hong Kong and Birmingham, UK.(Jiang et al., 2006) 
Recruitment of participants was in 3 phases. All participants were permanent residents of 
Guangzhou and members of “The Guangzhou Health and Happiness Association for the 
Respectable Elders” (GHHARE), a community social and welfare association unofficially 
aligned with the municipal government. Membership is open to older people for a monthly fee of 
4 Yuan (50 US cents). About 7% of permanent Guangzhou residents aged 50+ years are 
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members of GHHARE, of whom 11% (about 10,000 participants) enrolled for each of phases 
one, two and three. The inclusion criteria were that they were capable of consenting, ambulatory, 
and not receiving treatment modalities which, if omitted, may result in immediate life-
threatening risk, such as chemotherapy or radiotherapy for cancer, or dialysis for renal failure. 
The methods of measurement have previously been reported (Jiang et al., 2006). In brief, a 
medical interview was conducted using a standardized structured questionnaire, which covered 
socioeconomic position (including occupation, income, education), lifestyle (including smoking, 
physical activity and alcohol use), and health related questions (including past medical history). 
Age at menarche was recorded in years (as per the Gregorian calendar and related interpretation 
of age), rounded during data collection to the nearest year (e.g., 13 years represents the onset of 
menarche from 12 years 6 months to 13 years 5 months) (Heys et al., 2007). Physical 
examinations included measurement of seated blood pressure as the average of the last 2 of 3 
measurements, using the Omron 705 CP sphygmomanometer (Omron Corp, Kyoto, Japan), 
measurement of standing height, without shoes, to the nearest 0.1 cm, measurement of weight (in 
light clothing) to the nearest 0.1 kg, measurement of hip circumference at the greatest 
circumference round the buttocks below the iliac crest and measurement of waist circumference 
horizontally around the smallest circumference between the ribs and iliac crest, or at the navel 
for obese participants. Low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) 
cholesterol, triglycerides, and glucose were determined with a Shimadzu CL-8000 clinical 
chemical analyzer (Shimadzu Corp, Kyoto, Japan) in the hospital laboratory. 
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The Guangzhou Medical Ethics Committee of the Chinese Medical Association approved GBCS, 
including the use of genetic data. All participants gave written, informed consent prior to 
participation.  
 
DNA extraction and single nucleotide polymorphisms (SNP) analysis 
DNA was extracted at Guangzhou Number 12 Hospital from buffy coat previously stored at -
80°C using a standard magnetic bead extraction procedure (MagPure Blood DNA Mini Kit). All 
DNA concentrations were checked by Nanodrop (Thermoscientific, USA). For DNAs 
concentrations lower than 15 ng/µl, silica-based column method was also used to re-extract DNA 
manually (HiPure Blood DNA Mini Kit). 92% of the DNA samples passed quality control before 
genotyping. Genotyping was performed using the MassARRAY Sequenom platform (San Diego, 
CA, USA) at the Beijing Genomics Institute (BGI), Beijing. The average genotyping call rate of 
these SNPs was 98%. 
 
Instruments 
Replication of genetic predictors of age of menarche identified in Europeans in East Asians was 
not available at the time of conduct of study. As such, we a-priori selected the 12 SNPs 
previously reported to be strongly associated with age at menarche which were variant in East 
Asian populations, including SNPs from SPOCK (rs13357391, rs1859345, rs2348186, 
rs7701979),CCDC85A (rs17268785), the 9q31.2 region (rs2090409, rs4452860, rs7861820) and 
LIN28B (rs314276, rs369065, rs4946651, rs7759938).(Dvornyk and Waqar-ul-Haq, 2012) From 
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these 12 SNPs a parsimonious set predicting age of menarche in our setting were selected using 
stepwise regression, and were combined into a genetic allele score to reduce the likelihood of 
weak instrument bias (Lawlor et al., 2008).  
 
Exposure 
The exposure was age at menarche, recorded in years (to the nearest 0.5 years). 
 
Outcome 
The outcomes were cardiovascular disease risk factors. These included systolic and diastolic 
blood pressure (mmHg), LDL cholesterol (mmol/L), HDL cholesterol (mmol/L), log transformed 
triglycerides, fasting glucose (mmol/L), BMI, calculated  as weight /height2 (kg/m2), waist hip 
ratio (WHR) and type 2 diabetes. Type 2 diabetes was defined as fasting plasma glucose ≥7.0 
mmol/L or use of anti-diabetic medication. 
 
Control outcome 
Height was included as a control outcome. 
 
Statistical analysis 
We tested for Hardy-Weinberg equilibrium at the SNP locus on a contingency table of observed-
versus-predicted frequencies with an exact test. SNPs which deviated from the equilibrium were 
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discarded. Correlations between these SNPs were evaluated from the r2 measure of linkage 
disequilibrium obtained from SNP Annotation and Proxy Search 
(http://www.broad.mit.edu/mpg/snap/ldsearchpw.php) using the available HapMap (release #22, 
JPT+CHB) reference. For SNPs in linkage disequilibrium (r2≥0.8) the SNP with a larger p-value 
and/or a smaller effect size was discarded. We used stepwise linear regression to find a 
parsimonious set of SNPs which best predicted age at menarche. The significance level was set 
at 0.20 to ensure that the initial inclusion criterion was not too restrictive, as used in our previous 
paper.(Zhao et al., 2014) To reduce the likelihood of false positive in the selection of SNPs based 
on only one overall sample we also used 10-fold cross validation (k=10).(Schonlau, 2005)  The F 
statistic for the regression of age at menarche on genetic score (combined from the selected 
SNPs identified in the stepwise regression) was obtained, where a value ≥10 indicates that weak 
instrument bias is unlikely (Lawlor et al., 2008). We used analysis of variance (ANOVA) to 
assess whether age at menarche was associated with potential confounders. We also used 
ANOVA to assess whether the genetically estimated age at menarche was associated with 
potential confounders. We conducted instrumental variable analysis using 2 stage least squares 
(2SLS), with the genetic score as the instrument, to assess the association of age at menarche 
with continuous cardiovascular risk factors and with the log odds of diabetes. For comparison, 
we also present the multivariable linear and logistic regression analysis for the association of age 
at menarche with cardiovascular risk factors and height, adjusting for potential confounders 
including education, and recruitment phase (model 1).We also presented an additional model 
which we additionally adjusted for any cause of exposure or outcome as a potential confounding, 
including age, smoking, alcohol use, physical activity, job type, and corresponding medications 
such as antihypertensive for blood pressure (model 2) (VanderWeele and Shpitser, 2011). 
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All statistical analyses were conducted using Stata 13.1 (StataCorp LP, College Station, Texas, 
USA). 
 
Results 
Among 22,054 women in GBCS, 12,827 women had at least one SNP. rs369065 and rs2348186 
deviated from Hardy Weinberg equilibrium (p=0.04 and p<0.001 respectively) and were 
discarded. rs13357391, rs1859345 and rs7701979; and rs4946651 and rs7759938 were highly 
correlated (r2≥0.8) although the strength of associations with age at menarche differed. Based on 
the observed p values and/or effect sizes, rs1859345 and rs4946651 were retained. rs314276 was 
not included as only 8,068 women (63%) had this SNP. From the stepwise regression with cross 
validation, rs17268785 (CCDC85A), rs1859345 (SPOCK), rs2090409 (9q31.2 region), 
rs4452860 (9q31.2 region) and rs4946651 (LIN28B) were identified as predicting age at 
menarche as these SNPs had a p value of ≤0.20 in at least 5 of the datasets (Appendix 1) and 
were used in the genetic allele score (F statistic 19.9, n=12,290). Table 1 shows the distribution 
of age at menarche across different sociodemographic and lifestyle factors. Women with older 
age at menarche tended to be older, current smokers, and never drinkers, as well as being less 
educated and having a manual job. Table 2 shows that genetically estimated age at menarche was 
not associated with age, smoking, physical activity, education, or job type. Although genetically 
estimated age at menarche was associated with alcohol use, the difference was very small. 
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Table 3 shows that observationally older age at menarche was associated with lower LDL 
cholesterol, log transformed triglycerides, glucose, BMI and risk of type 2 diabetes and was 
associated with higher waist hip ratio and taller height in model 1 which only included common 
causes of exposure and outcome. However, when additionally adjusted for any cause of exposure 
or outcome (model 2), older age at menarche was only associated with lower LDL cholesterol, 
log transformed triglycerides, body mass index, lower risk of type 2 diabetes and remained 
associated with taller height. In the Mendelian randomization analysis older age at menarche was 
associated with lower glucose (-0.39 mmol/L per year, 95%CI -0.78 to -0.001) but was not 
clearly associated with any other cardiovascular risk factor, although the wide confidence 
interval preclude definitive refutation. For example, the estimates for blood pressure, BMI and 
diabetes were all in the direction of older age of menarche being associated with lower point 
estimates, but the confidence intervals included null. Older age at menarche was associated with 
the positive control, i.e. height. Repeating the analyses using an allele score without rs2090409 
and rs4452860, which did not replicate well in the cross validation (Appendix 1), showed 
directionally similar results although estimates had wider confidence intervals (Appendix 2). 
Repeating the analysis excluding samples with re-extraction (10% of the original samples have 
their DNA re-extracted) did not change the conclusion for Mendelian randomization (data not 
shown). 
 
Discussion 
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This is the first Mendelian randomization study on age at menarche with cardiovascular disease 
risk factors where we found age at menarche inversely associated with glucose, and positively 
associated with height as expected.  
 
The inverse association of age at menarche with cardiovascular risk factors has been consistently 
seen in different settings (Chang et al., 2011; Feng et al., 2008; Gallagher et al., 2011; Heys et al., 
2007; Lakshman et al., 2009). Our findings suggest that some of the observed associations could 
be confounded such as childhood obesity, early life infections (Kwok et al., 2011), or other 
drivers of growth. A previous Mendelian randomization study (n=8,156) showed that girls with 
higher childhood BMI had a higher absolute risk of early menarche (<12 years) (Mumby et al., 
2011). Childhood BMI is also a strong predictor of adult obesity where a recent meta-analysis 
showed that obese children are 5 times more likely to be obese in adulthood compared to non-
obese children (Simmonds et al., 2016). As such, childhood BMI may confound the association 
of age at menarche with cardiovascular disease via its relation with adulthood BMI which in turn 
causes cardiovascular disease (Kivimaki et al., 2008; Nordestgaard et al., 2012). However, the 
women in our study grew up in China in the 1940s and 1950s during periods of significant 
hardship, making this an unlikely explanation for the inverse association in our observational 
analysis.. Similarly, a recent study from China showed that the association of age at menarche 
with cardiovascular disease was more evident in younger cohorts than older cohorts (Yang et al., 
2017). Such differences could be explained by cohort effects but alternatively could be a result of 
confounding since more recent generations of Chinese women grew up in a more obesogenic 
environment, making the confounding effect of childhood obesity more influential. Early life 
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infections are associated with later age at menarche (McDonald et al., 2016), but are not thought 
to protect against cardiovascular disease risk factors.   
 
Earlier uptake of unhealthy lifestyle with earlier puberty may explain findings from previous 
studies although such pathway was not supported by our previous study (Heys et al., 2007). 
Alternatively, earlier age at menarche generates greater exposure to endogenous sex hormones, 
which may explain the association of younger age of menarche with type 2 diabetes (He et al., 
2010). Consistent with this explanation, both estrogen and younger age at menarche are 
associated with higher risk of breast cancer. (Collaborative Group on Hormonal Factors in Breast, 
2012; Rossouw et al., 2002). However, contrary to this explanation,  randomized controlled trials 
also showed that estrogen reduces the risk of diabetes (Margolis et al., 2004), which is 
inconsistent with an association of older age at menarche with lower glucose operating through 
such a pathway. Such discrepancies suggest the relation of age at menarche with cardiovascular 
risk may not simply be a reflection of the effects of lifelong estrogen exposure. Alternatively, 
some drivers of growth, such as growth hormone, may increase the risk of diabetes (Cutfield et 
al., 2000). Therefore, slower growth could underlie the inverse association of menarche and 
fasting glucose. Growth hormone is associated with lower blood pressure and LDL cholesterol in 
clinical trials (Maison et al., 2004), which suggests it should decrease cardiovascular risk, but 
these trials were among people with growth hormone deficiency which may not generalize to the 
general population.  
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The genetic predictors we used for age at menarche included SNPs from CCDC85A, SPOCK, 
9q31.2 region and LIN28B. SNPs near CCDC85A have been associated with diabetes (Imamura 
et al., 2016). SPOCK is related to proteoglycan and inhibits matrix metalloproteinase -2 
activations (Liu et al., 2009), but its function is not clearly understood. The 9q31.2 region is 
associated with breast cancer (Orr et al., 2015). LIN28B encodes a developmentally regulated 
RNA binding protein (He et al., 2009), and is associated with several cancers (Viswanathan et al., 
2009). Given the function of these gene regions remains to be fully clarified, we may have 
included SNPs which have direct effects on glucose other than via menarche, and hence violated 
the exclusion restriction assumption. The SNP with the strongest effect on fasting glucose was 
rs1859345 (SPOCK) instead of rs17268785 (CCDC85A). Over 100 genetic loci have been 
associated with age at menarche, so it is possible that our genetic instrument did not encompass 
all the different domains, such as those in hormone synthesis and bioactivity, and energy 
homeostasis and growth (Perry et al., 2014), that age at menarche represents and hence only 
found an association with fasting glucose. However, we also found the expected relation for 
height. 
 
We used a Mendelian randomization study which is less susceptible to confounding, nevertheless 
limitations exist. First, Mendelian randomization studies have stringent assumptions which 
cannot be empirically verified. However, the findings from this study are mainly null and null 
findings are potentially more reliable in the context of Mendelian randomization studies 
(VanderWeele et al., 2014). Age at menarche is invariant and is less susceptible to the violation 
of assumption where the predictors of the exposures only act on the outcomes through the 
exposure (exclusion-restriction assumption) compared to time varying exposures , such as body 
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mass index, that may directly affect the outcome at some times (VanderWeele et al., 2014). Age 
at menarche being invariant also means that genetic associations with age of menarche are less 
likely to represent correlations with other factors associated with the exposure that may 
accumulate over the lifespan. Although there remains a possibility of misclassification as age at 
menarche was based on recall, a previous study comparing recalled and original age at menarche 
showed reasonable correlations (Must et al., 2002). We used height as a positive control outcome 
and a large sample size to reduce the likelihood of false negatives in the main analyses (Freeman 
et al., 2013). However, some estimates had wide confidence intervals and hence larger 
Mendelian randomization studies are needed to verify our findings since there might be small 
cardiovascular effects of age at menarche which could still be meaningful from a public health 
perspective. Second, the SNPs predicting age at menarche were from Western populations but 
did not replicate well in our study (Dvornyk and Waqar-ul-Haq, 2012), as well as in another 
Asian study (Shi et al., 2016). This discrepancy may have arisen because of the difference 
between the populations studied in the environmental factors driving age at menarche, such as 
obesity. Although the small number of genetic variants was compensated for by a large sample 
size, as reflected by an F statistic of 19.9, weak instrument bias due to winner’s curse may bias 
our estimates towards the confounded observational estimate (Lawlor, 2016). However, similar 
associations were seen when we only selected instruments after cross validation, suggesting the 
association seen in our analyses are not primarily driven by weak instrument bias. . Third, 
cardiovascular disease events are not high in our cohort (e.g. we only had 410  participants with 
self-reported ischemic heart disease among women included in this study) and are still 
accumulating so we could not draw a direct link between age at menarche and cardiovascular 
disease prospectively in this study, which would require a very large sample size with enough 
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cases given the low variance in age at menarche explained by genetics (2.7% for 123 SNPs) 
(Perry et al., 2014). The use of summary statistics from genome wide association studies may 
circumvent some of these limitations (Lawlor, 2016). However, existing genome wide 
association studies do not give sex-specific summary estimates and thus may not be suited for 
answering research questions which are sex specific, such as the health effects of age at 
menarche. Fourth, we cannot rule out the possibility that the association of age at menarche with 
cardiovascular risk has a U shape relation based on previous studies (Canoy et al., 2015; Yang et 
al., 2017). Although conducting Mendelian randomization by stratum of age at menarche may 
delineate potential non-linear relation, this would inevitably lead to imprecise stratum-specific 
estimates which could obscure the true exposure-outcome relation, as well as potentially 
generating weak instrumental biases due to reduced sample size in each stratified analysis 
(Burgess et al., 2014). Nevertheless, the potential U shape relation could be examined in future 
studies with larger cohorts with genetic data such as the UK Biobank or the China Kadoorie 
Biobank (Allen et al., 2014; Chen et al., 2005). Lastly, we did not have SNPs for all GBCS 
participants as DNA was only available for those who attended the follow up. However, our 
estimates would only be biased if the genotypes determined follow up, which is unlikely.  
 
Conclusion 
Our study found little evidence that age at menarche affects traditional cardiovascular disease 
risk factors except an inverse relation with glucose. As such, the secular trend of decreasing age 
at menarche and increasing cardiovascular disease in settings undergoing rapid economic 
development, such as Asia and Africa, or previous observational studies showing an association 
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between age at menarche and cardiovascular disease could be confounded by factors such as 
childhood obesity. Adequately powered Mendelian randomization studies with cardiovascular 
outcomes and diabetes will be needed to ascertain the relation of age at menarche with these 
outcomes allowing for the possibility that childhood obesity drives age at menarche. 
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Table 1: Age at menarche by lifestyle and socio-demographics among 12,705 Southern  
Chinese older women in the Guangzhou Biobank Cohort Study (2003-8) 
Characteristic  Sample size Age at menarche (SD) 
aP value 
Age group  50-54 3,337 14.3 (1.8) <0.001 
 55-59 3,625 14.8 (1.9)   
 60-64 2,405 15.3 (2.1)  
 65-69 2,068 15.4 (2.0)  
 70-74 1,015 15.8 (2.1)  
 75-79 213 15.9 (2.2)   
 80+ 42 15.4 (2.2)  
     
Smoking status Never smokers 12,344 14.9 (2.0) 0.005 
 Former smokers 167 15.5 (2.0)  
 Current smokers 180 15.0 (2.1)  
     
Alcohol status Never drinkers 9,866 15.0 (2.0) <0.001 
 Former drinkers 330 14.9 (2.3)  
 Current drinkers 2,432 14.8 (2.0)  
     bPhysical activity  Inactive 1,041 14.9 (2.1) 0.51 
(IPAQ) Minimally active 4,890 15.0 (2.0)  
 HEPA active 6,774 15.0 (2.1)  
     
Education Less than primary 1,271 16.2 (2.2) <0.001 
 Primary 4,219 15.4 (2.0)  
 Junior middle 3,448 14.7 (1.9)  
 Senior middle 2,977 14.3 (1.8)  
 Junior college 568 14.1 (1.7)  
 College 220 14.5 (2.1)  
     cLongest-held  Manual  8,411 15.1 (2.1) <0.001 
occupation Non-manual 2,463 14.6 (1.9)  
 Others 1,752 14.7 (1.9)  aP value obtained from analysis of variance (ANOVA) 
bHEPA: Health-enhancing physical activity (i.e. vigorous activity at least 3 days a week 
achieving at least 1500 metabolic equivalent (MET) minutes per week or activity on 7 days of 
the week, achieving at least 3000 MET minutes per week (IPAQ: International Physical Activity 
Questionnaire). 
cManual occupations are agricultural worker, factory work or sales and service; non-manual are 
administrator/ manager, professional/technical, military/disciplined. 
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Table 2: Genetically estimated age at menarche by lifestyle and socio-demographics  
among 12,410 Southern Chinese older women in the Guangzhou Biobank Cohort Study (2003-8) 
Characteristic  Sample size 
Genetically estimated 
age at menarche 
aP value 
Age group  50-54 3,271 14.96 (0.08) 0.59 
 55-59 3,517 14.96 (0.08)  
 60-64 2,348 14.96 (0.08)  
 65-69 2,015 14.96 (0.08)  
 70-74 1,006 14.96 (0.08)  
 75-79 208 14.96 (0.09)  
 80+ 45 14.94 (0.08)  
     
Smoking status Never smokers 12,051 14.96 (0.08) 0.10 
 Former smokers 163 14.95 (0.09)  
 Current smokers 181 14.95 (0.08)  
     
Alcohol status Never drinkers 9,626 14.96 (0.08) 0.02 
 Former drinkers 325 14.96 (0.08)  
 Current drinkers 2,382 14.95 (0.08)  
     bPhysical activity  Inactive 1,014 14.96 (0.09) 0.55 
(IPAQ) Minimally active 4,762 14.96 (0.08)  
 HEPA active 6,634 14.96 (0.08)  
     
Education Less than primary 1,243 14.96 (0.08) 0.77 
 Primary 4,136 14.96 (0.08)  
 Junior middle 3,355 14.96 (0.08)  
 Senior middle 2,912 14.96 (0.08)  
 Junior college 548 14.96 (0.09)  
 College 214 14.96 (0.08)  
     cLongest-held  Manual  8,233 14.96 (0.08) 0.66 
occupation Non-manual 2,393 14.96 (0.08)  
 Others 1,704 14.96 (0.08)  aP value obtained from analysis of variance (ANOVA) 
bHEPA: Health-enhancing physical activity (i.e. vigorous activity at least 3 days a week 
achieving at least 1500 metabolic equivalent (MET) minutes per week or activity on 7 days of 
the week, achieving at least 3000 MET minutes per week (IPAQ: International Physical Activity 
Questionnaire). 
cManual occupations are agricultural worker, factory work or sales and service; non-manual are 
administrator/ manager, professional/technical, military/disciplined. 
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Table 3: Association of age at menarche (years) and cardiovascular risk factors, type 2 diabetes, and height among 12,692 Southern 
Chinese older women in the Guangzhou Biobank Cohort Study (2003-8) using Mendelian randomization and multivariable regression 
analysis 
 
Mendelian randomization aMultivariable regression (Model 1) aMultivariable regression (Model 2) 
 
n β 95% CI n β 95% CI n β 95% CI 
Systolic blood pressure (mmHg) 12,270 -2.46 -7.40 to 2.48 12,682 0.11 -0.08 to 0.30 12,517 0.07 -0.10 to  0.25 
 
         
Diastolic blood pressure (mmHg) 12,270 -1.62 -4.13 to 0.88 12,683 -0.06 -0.15 to 0.04 12,518 0.06 -0.03 to 0.16 
 
         
HDL cholesterol (mmol/L) 12,256 0.02 -0.07 to 0.10 12,667 -0.002 -0.006 to 0.001 12,496 -0.002 -0.005 to 0.002 
 
         
LDL cholesterol (mmol/L) 12,232 0.06 -0.10 to 0.21 12,642 -0.015 -0.02 to -0.008 12,471 -0.016 -0.02 to -0.009 
 
         
Log transformed triglycerides 12,260 -0.05 -0.17 to 0.06 12,670 -0.01 -0.01 to -0.005 12,499 -0.01 -0.02 to -0.006 
 
         
Fasting glucose (mmol/L) 12,229 -0.39 -0.78 to -0.001 12,640 -0.02 -0.03 to -0.002 12,468 -0.003 -0.02 to 0.009 
 
         
Body mass index (kg/m2) 12,270 -0.24 -0.96 to 0.49 12,683 -0.12 -0.15 to -0.09 12,524 -0.12 -0.15 to -0.09 
 
         
Waist hip ratio 12,259 -0.003 -0.02 to 0.01 12,670 0.0009 0.0003 to 0.001 12,511 0.00 -0.0003 to 0.0008  
 
         
Presence of diabetes (odds ratio) 12,231 0.65 0.32 to 1.33 12,642 0.94 0.91 to 0.97 12,484 0.92 0.89 to 0.95 
          
Height (cm) 12,279 1.36 0.04 to 2.69 12,692 0.13 0.08 to 0.17 12,533 0.19 0.14 to 0.24 
aModel 1 adjusted for education level and recruitment phase; Model 2 additionally adjusted for age, smoking, alcohol use, physical activity, job 
type, and corresponding medications such as antihypertensive for blood pressure. 
HDL: High density lipoprotein; LDL: Low density lipoprotein
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Appendix 1: P values for each single nucleotide polymorphism (SNP) in each training+validation pair in 
the 10-fold cross validation  
P value ≤0.20 were bolded 
 
 
  
 Training+Validation pair in the 10-fold cross validation  
SNP 1 2 3 4 5 6 7 8 9 10 
Number of datasets which P≤ 0.2  
for the corresponding SNP 
rs17268785 0.15 0.10 0.14 0.15 0.11 0.04 0.10 0.25 0.07 0.14 9 
rs1859345 0.04 0.13 0.06 0.11 0.19 0.28 0.12 0.08 0.04 0.16 9 
rs2090409 0.32 0.53 0.18 0.35 0.14 0.18 0.24 0.12 0.32 0.05 5 
rs4452860 0.19 0.42 0.11 0.27 0.12 0.11 0.20 0.08 0.21 0.03 7 
rs4946651 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 10 
rs7861820 0.80 0.33 0.45 0.19 0.54 0.54 0.25 0.39 0.48 0.53 1 
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Appendix 2: Association of age at menarche (years) and cardiovascular risk factors, type 2 
diabetes, and height among 12,410 Southern Chinese older women in the Guangzhou Biobank 
Cohort Study (2003-8) using Mendelian randomization excluding less consistent single 
nucleotide polymorphisms (rs2090409 and rs4452860) in the cross validation 
  Excluding rs2090409 and rs4452860 (F statistics: 16.9)  
  n β 95% CI 
Systolic blood pressure (mmHg) 12,401 -2.40 -7.68 to 2.88 
 
   
Diastolic blood pressure (mmHg) 12,401 -1.17 -3.79 to 1.45 
 
   
High density lipoprotein cholesterol (mmol/L) 12,386 0.01 -0.08 to 0.10 
 
   
Low density lipoprotein cholesterol (mmol/L) 12,361 0.06 -0.11 to 0.22 
 
   
Log transformed triglycerides 12,390 -0.05 -0.17 to 0.07 
 
   
Fasting glucose (mmol/L) 12,359 -0.43 -0.85 to -0.003 
 
   
Body mass index (kg/m2) 12,401 -0.28 -1.06 to 0.50 
 
   
Waist hip ratio 12,389 -0.005 -0.02 to 0.01 
 
   
Presence of diabetes (odds ratio) 12,361 0.60 0.27 to 1.30 
    
Height (cm) 12,410 1.39 -0.03 to 2.82 
 
 
 
